@article{3120012,
    title = "Fungal lung disease",
    author = "Koltsida, G. and Zaoutis, T.",
    journal = "Paediatric Respiratory Reviews",
    year = "2021",
    volume = "37",
    pages = "99-104",
    publisher = "W.B. Saunders Ltd",
    issn = "1526-0542",
    doi = "10.1016/j.prrv.2020.04.009",
    keywords = "amphotericin B;  atovaquone;  clindamycin;  corticosteroid;  cotrimoxazole;  dapsone;  fluconazole;  flucytosine;  isavuconazole;  itraconazole;  ketoconazole;  pentamidine;  posaconazole;  primaquine;  trimethoprim;  mycosis, allergic bronchopulmonary aspergillosis;  antibiotic prophylaxis;  aspergilloma;  blastomycosis;  coccidioidomycosis;  cystic fibrosis;  drug megadose;  fungal colonization;  histoplasmosis;  human;  immunocompromised patient;  invasive aspergillosis;  lung mycosis;  mucormycosis;  Pneumocystis pneumonia;  priority journal;  pseudallescheriasis;  pulmonary candidiasis;  pulmonary cryptococcosis;  Review;  child;  cystic fibrosis;  fungus;  Scedosporium, Child;  Cystic Fibrosis;  Fungi;  Humans;  Lung Diseases, Fungal;  Mycoses;  Scedosporium",
    abstract = "Fungal lung disease in the paediatric population occurs with distinct features in the immunocompetent, in immunocompromised patients and in people with cystic fibrosis. Pulmonary mycoses are the least prevalent in immunocompetent children, with the most common diseases being the endemic mycoses and Aspergillomas. Filamentous fungi such as Aspergillus and Scedosporium have been isolated with increased frequency in recent years from the respiratory secretions of individuals with cystic fibrosis. Undoubtedly, fungal respiratory infections are encountered with increased frequency and severity in patients with impaired immune systems, such as patients with malignancies, solid organ or bone marrow transplants and immunodeficiencies [1]. © 2020"
}